In contrast to circulating levels of LIF in serum, there was no significant difference in LIF mRNA expression in pre-treatment OAC tumour biopsies from good and poor responders to neoadjuvant treatment (Figure 3B) indicating that LIF in the circulation may be a more important predictive marker of treatment response than expression levels of LIF within the tumour. This evidence concerns the gene LIF and neoplasm.